Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 6Phase 3 3Phase 1 3Phase 4 1Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

Brentuximab Vedotin 3relmacabtagene autoleucel 2fludarabine phosphate 2fludarabine 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 2xihuang 1tocilizumab 1tislelizumab 1sofosbuvir-velpatasvir drug combination 1sintilimab 1rasburicase 1ledipasvir 1entecavir 1apatinib 1aflibercept 1acalabrutinib 1Urate Oxidase 1Trabectedin 1Thiotepa 1Thalidomide 1Tenofovir 1Tamsulosin 1Sofosbuvir 1Sevoflurane 1Rivaroxaban 1Ribavirin 1Radiotherapy 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Recurrence × Bendamustine Hydrochloride × Clear all
NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡